EMA Authorised: Byetta (exenatide) — AstraZeneca AB

View source ↗

Summary

The EMA authorised Byetta (exenatide) for the treatment of Type 2 diabetes mellitus; decision date: 05 November 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BYETTA (Exenatide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: AstraZeneca AB. Decision date: 05/11/2024